0001001907 astrotech公司 --06-30 Q1 2025 0.001 0.001 2,500,000 2,500,000 280,898 280,898 280,898 280,898 0.001 0.001 250,000,000 250,000,000 1,712,045 1,712,045 1,701,729 1,701,729 10,316 10,316 31 http://fasb.org/us-gaap/2024#固定资产净额 http://fasb.org/us-gaap/2024#资产负债表和设备净额 http://www.astrotechcorp.com/20240930#运营与财务租赁负债当前 http://www.astrotechcorp.com/20240930#运营与财务租赁负债当前 http://www.astrotechcorp.com/20240930#运营与财务租赁负债当前 http://www.astrotechcorp.com/20240930#运营与财务租赁负债当前 http://www.astrotechcorp.com/20240930#OperatingAndFinanceLeasesLiabilityNoncurrent http://www.astrotechcorp.com/20240930#OperatingAndFinanceLeasesLiabilityNoncurrent http://www.astrotechcorp.com/20240930#OperatingAndFinanceLeasesLiabilityNoncurrent http://www.astrotechcorp.com/20240930#OperatingAndFinanceLeasesLiabilityNoncurrent 45 31 0 0 1 2 0 21 00010019072024-07-012024-09-30 xbrli:股份 00010019072024-11-08 thunderdome:item iso4217:美元指数 00010019072024-09-30 00010019072024-06-30 iso4217:美元指数xbrli:股份 00010019072023-07-012023-09-30 0001001907us-gaap:系列D优先股成员us-gaap: 优先股成员2024-06-30 0001001907astc:CommonStockOutstandingMember2024-06-30 0001001907美国通用会计准则:普通股库藏股份成员2024-06-30 0001001907us-gaap:额外缴入资本成员2024-06-30 0001001907us-gaap:保留盈余成员2024-06-30 0001001907us-gaap:其他综合收益累计会员2024-06-30 0001001907us-gaap:系列D优先股成员us-gaap:优先股成员2024-07-012024-09-30 0001001907astc : 普通股未偿还成员2024-07-012024-09-30 0001001907us-gaap:库存股普通股成员2024-07-012024-09-30 0001001907us-gaap:追加实收资本成员2024-07-012024-09-30 0001001907us-gaap:留存收益成员2024-07-012024-09-30 0001001907us-gaap:累计其他综合收益成员2024-07-012024-09-30 0001001907us-gaap:系列D优先股成员us-gaap:优先股成员2024-09-30 0001001907astc : 流通普通股成员2024-09-30 0001001907us-gaap:库藏普通股成员2024-09-30 0001001907us-gaap:追加实收资本成员2024-09-30 0001001907us-gaap:留存收益成员2024-09-30 0001001907us-gaap:累计其他综合收入成员2024-09-30 0001001907us-gaap:系列D优先股成员us-gaap:优先股成员2023-06-30 0001001907astc : 流通普通股成员2023-06-30 0001001907us-gaap:库存普通股成员2023-06-30 0001001907us-gaap:额外资本公积成员2023-06-30 0001001907us-gaap:留存收益成员2023-06-30 0001001907us-gaap:累计其他综合收益成员2023-06-30 00010019072023-06-30 0001001907us-gaap:D系列优先股票成员us-gaap:优先股票成员2023-07-012023-09-30 0001001907astc : 流通普通股成员2023-07-012023-09-30 0001001907us-gaap:库存普通股成员2023-07-012023-09-30 0001001907us-gaap:额外实收资本成员2023-07-012023-09-30 0001001907us-gaap:留存收益成员2023-07-012023-09-30 0001001907us-gaap:累计其他综合收益成员2023-07-012023-09-30 0001001907us-gaap:系列D优先股成员us-gaap:优先股成员2023-09-30 0001001907astc : 普通股已发行成员2023-09-30 0001001907us-gaap:库存股票普通股成员2023-09-30 0001001907us-gaap:股本溢价成员2023-09-30 0001001907us-gaap:未分配利润成员2023-09-30 0001001907us-gaap:累计其他全面收益成员2023-09-30 00010019072023-09-30 0001001907astc:企业政府债务互助基金证券会员2024-09-30 0001001907astc:企业政府债券ETF证券会员2024-09-30 0001001907astrotech : 企业政府债务共同基金证券会员2024-06-30 0001001907astrotech : 企业政府债务ETF证券会员2024-06-30 平方英尺 0001001907研发设施会员奥斯汀,德克萨斯会员2021-04-27 utr:M 0001001907astrotech : 研发设施会员astc : 奥斯汀德克萨斯州会员2022-11-11 0001001907子租设施会员astc : 奥斯汀德克萨斯州会员2022-11-22 0001001907astc : 转租设施会员astc : 奥斯汀德克萨斯州会员2022-12-01 utr:是 xbrli:纯形 0001001907家具、装置和租赁改善会员2024-09-30 0001001907astrotech : 家具、固定装置、设备和租赁改进成员2024-06-30 0001001907us-gaap:软件和软件开发成本成员2024-09-30 0001001907美国通用会计准则: 软件与软件开发成本成员2024-06-30 0001001907美国通用会计准则:在建工程成员2024-09-30 0001001907美国通用会计准则: 在建工程成员2024-06-30 0001001907astc:权利计划成员2022-12-21 00010019072023-07-012024-06-30 0001001907美元指数:限制性股票会员2024-07-012024-09-30 0001001907us-gaap:员工股票期权成员2024-07-012024-09-30 0001001907美国通用会计准则:短期投资成员us-gaap:账面报告金额公允价值披露成员astrotech : 企业政府债务共同基金证券成员2024-09-30 0001001907us-gaap:短期投资成员美国会计准则:公允价值输入一级成员us-gaap:公允价值估计公允价值披露成员astrotech : 企业政府债务共同基金证券成员2024-09-30 0001001907us-gaap:短期投资成员美国通用会计准则:公平值输入二级成员us-gaap:公允价值的估计公允价值信息成员astc : 公司政府债务共同基金证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入层级3成员us-gaap:公允价值的估计公允价值信息成员astc : 公司政府债务共同基金证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值估计公允价值披露成员astc : 企业政府债务共同基金证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:账面报告金额公允价值披露成员astc : 企业政府债务ETF证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入级别1成员us-gaap:公允价值估计公允价值披露成员astc : 公司政府债务ET Fs证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入等级2成员us-gaap:公允价值估计公允价值披露成员astc : 公司政府债务ET Fs证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入等级3成员us-gaap:公允价值估计公允价值披露成员astc : 企业政府债务ET Fs证券成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:公允价值估计公允价值披露成员astc : 企业政府债务ET Fs证券成员2024-09-30 0001001907us-gaap:账面报告金额公允价值披露成员2024-09-30 0001001907us-gaap:公允价值输入级别1成员us-gaap:公允价值估计公允价值披露成员2024-09-30 0001001907us-gaap:公允价值输入级别2成员us-gaap:公允价值估计公允价值披露成员2024-09-30 0001001907us-gaap:公允价值输入水平3成员us-gaap:公允价值估计公允价值披露成员2024-09-30 0001001907us-gaap:公允价值估计公允价值披露成员2024-09-30 0001001907us-gaap:短期投资成员us-gaap:报告的账面金额公允价值披露成员astc : 企业政府债务共同基金证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公平价值输入层级1成员us-gaap:公平价值估计公平价值披露成员astc : 企业政府债务共同基金证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公平价值输入层级2成员us-gaap:公平价值估计公平价值披露成员astc : 企业政府债务共同基金证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入等级3成员us-gaap:公允价值估计公允价值披露成员astc : 企业政府债务共同基金证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值估计公允价值披露成员astc : 企业政府债务共同基金证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:报告金额公允价值披露成员astrotech : 公司政府债务ET Fs证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入等级1成员us-gaap:公允价值估计公允价值披露成员astrotech : 公司政府债务ET Fs证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入等级2成员us-gaap:公允价值估计公允价值披露成员astrotech : 企业政府债务ETFs证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值输入第3级成员us-gaap:公允价值估计公允价值披露成员astrotech : 企业政府债务ETFs证券成员2024-06-30 0001001907us-gaap:短期投资成员us-gaap:公允价值估计公允价值披露成员astrotech : 企业政府债务ETFs证券成员2024-06-30 0001001907us-gaap:报告金额与公允价值披露成员2024-06-30 0001001907us-gaap:公允价值输入水平1成员us-gaap:公允价值估计与公允价值披露成员2024-06-30 0001001907us-gaap:公允价值输入水平2成员us-gaap:公允价值估计与公允价值披露成员2024-06-30 0001001907us-gaap:公允价值输入水平3成员us-gaap:公允价值估计与公允价值披露成员2024-06-30 0001001907us-gaap:公允价值估计与公允价值披露成员2024-06-30 0001001907us-gaap:应收账款成员us-gaap:客户集中风险成员2024-07-012024-09-30 0001001907us-gaap:应收账款成员us-gaap:客户集中风险成员2023-07-012023-09-30 0001001907us-gaap:员工股票期权成员2024-09-30 0001001907astrotech:行权价格区间1成员2024-07-012024-09-30 0001001907astc : 行使价格区间 1 成员2024-09-30 0001001907astrotech:行权价格区间2成员2024-07-012024-09-30 0001001907astc : 行使价格区间 2 会员2024-09-30 0001001907astc:ExercisePriceRange3Member2024-07-012024-09-30 0001001907astc : 行使价格区间 3 会员2024-09-30 0001001907us-gaap:员工股票期权会员2024-07-012024-09-30 0001001907us-gaap:员工股票期权会员2023-07-012023-09-30 0001001907us-gaap:限制性股票会员2024-06-30 0001001907us-gaap:限制性股票会员2024-07-012024-09-30 0001001907us-gaap:限制性股票会员2024-09-30 0001001907us-gaap:限制性股票成员2023-07-012023-09-30
 

目录


美国

证券交易委员会

华盛顿特区 20549

 


表格 10-Q


 

(标记一个)

根据1934年证券交易法第13或15(d)条款的季度报告。

  

截至2024年6月30日季度结束 2024年9月30日

 

 

根据1934年证券交易法第13或15(d)条款的过渡报告

 

转型期间从_____________到_____________

 

委员会文件编号 001-34426

logo.jpg


astrotech 公司

 

(根据其章程所指定的正式名称)

 

德拉瓦

 

91-1273737

State or Other Jurisdiction of

设立或组织

 

联邦雇主识别号码

   

2105 Donley Drive,100号套房, 奥斯丁, 德克萨斯

 

78758

主要行政办公室地址

 

邮递区号

 

(512) 485-9530

申请人电话号码,包括区号

 

曾用名称、曾用地址及如果自上次报告以来有所更改的财政年度

 

根据法案第12(b)条规定注册的证券:

 

每种类别的名称

 

交易

标的

 

每个注册交易所的名称

普通股,每股面值0.001美元

 

逐笔明细

 

纳斯达克 股票市场,LLC

 

 

 

请点选勾号表示登记申请人(1)已在过去12个月里(或是在申请人应提交此类报告的期间中,以较短时间为准)提交了证券交易所法案第13或15(d)条所规定提交的所有报告,(2)申请人在过去90日内已履行过此类提交要求。Yes☒     否 ☐

 

请以√号表示,即在过去12个月内,公司是否按照《Regulation S-t》第405条(本章节第232.405条)的规定,提交了应提交的每个互动资料文件(或对于要求提交此类文件的较短期间的情况)。Yes☒  不是  ☐

 

勾选表示登记人是大型加速申报人、加速申报人、非加速申报人、较小型申报公司或新兴成长公司。详细定义请参阅《交易所法》第1202条中“大型加速申报人”、“加速申报人”、“较小型申报公司”和“新兴成长公司”的定义。

 

大型加速文件提交者

 

 

加速档案提交者

 

非加速归档人

 

 

较小报告公司

 

新兴成长型企业

 

    

 

如果是新兴成长公司,请勾选该选项,如果申报人选择不使用《交易法》第13(a)条所提供的新财务会计准则的延长过渡期符合。 ☐

 

请勾选选项,表明登记者是否为空壳公司(根据法案规则120亿2定义)。 是    否☒

 

截至2024年11月8日,注册公司的普通股流通股数为: [1,701,729].

 


 

 

 

 

astrotech公司及其子公司

第10-Q表格季报告

目录

 

   

页面

第一部分:

财务信息

3

     

ITEm 1.

未经审计的精简合并基本报表

3

ITEm 2.

财务状况和业绩的管理讨论和分析

18

项目 3。

市场风险相关数量和质量的披露

23

项目 4。

控制和程序

23

     

第二部分:

其他资讯

24

     

ITEm 1.

法律诉讼

24

项目1A.

风险因素

24

ITEm 2.

未注册的股票销售和收益使用

24

项目 3。

债券不履行标准

24

项目 4。

矿山安全披露

24

条目 5。

其他资讯

24

条目 6。

附件

25

 

 

 

2

 

 

第一部分:财务信息

 

项目 1。   基本报表汇编

 

ASTROTECH公司及其子公司

简明合并资产负债表

(单位为千,除股份和每股数据外)

                                                                                                                                                                                                                             

  九月三十日  6月30日 
  

2024

  

2024

 
  

(未经审计)

  

(注意)

 

资产

        

流动资产

        

现金及现金等价物

 $6,518  $10,442 

短期投资

  21,790   21,474 

应收账款

  91   77 

库存,净值:

        

原材料

  2,212   2,038 

在制品

  177   66 

成品

  309   370 

预付款项及其他流动资产

  515   261 

总流动资产

  31,612   34,728 

物业及设备(净额)

  2,724   2,763 

经营租赁使用权资产,净额

  83   119 

其他资产,净值

  30   30 

总资产

 $34,449  $37,640 

负债和股东权益

        

流动负债

        

应付账款

 $649  $373 

与薪资相关的应计费用

  612   1,174 

应计费用和其他负债

  717   754 

租赁负债,当前

  149   227 

总流动负债

  2,127   2,528 

应计费用及其他负债,扣除当前部分

  194   232 

租赁负债,减去流动部分

  67   73 

总负债

  2,388   2,833 

承诺和或有事项(注释13)

          

股东权益

        

可转换优先股,$0.001 面值, 2,500,000 授权股份; 280,898 截至2024年9月30日和2024年6月30日已发行和流通的D类股股份

      

普通股,$0.001 面值, 250,000,000 截至2024年9月30日和2024年6月30日的授权股份 1,712,045 截至2024年9月30日和2024年6月30日已发行的股份 1,701,729 截至2024年9月30日和2024年6月30日的流通股份

  190,643   190,643 

库藏股, 10,316 截至2024年9月30日和2024年6月30日

  (119)  (119)

额外实收资本

  82,696   82,480 

累计亏损

  (240,298)  (237,020)

累计其他综合损失

  (861)  (1,177)

股东权益总额

  32,061   34,807 

总负债和股东权益

 $34,449  $37,640 

 

Note: The condensed consolidated balance sheet at June 30, 2024, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

ASTROTECH CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

 

   

Three Months Ended

 
   

September 30,

 
   

2024

   

2023

 

Revenue

  $ 34     $ 425  

Cost of revenue

    25       242  

Gross profit

    9       183  

Operating expenses:

               

Selling, general and administrative

    1,688       1,646  

Research and development

    1,949       1,872  

Total operating expenses

    3,637       3,518  

Loss from operations

    (3,628 )     (3,335 )

Other income and expense, net

    350       423  

Loss from operations before income taxes

    (3,278 )     (2,912 )

Income tax expense

           

Net loss

  $ (3,278 )   $ (2,912 )

Weighted average common shares outstanding:

               

Basic and diluted

    1,631       1,631  

Basic and diluted net loss per common share:

               

Net loss per common share

  $ (2.01 )   $ (1.79 )

Other comprehensive loss, net of tax:

               

Net loss

  $ (3,278 )   $ (2,912 )

Available-for-sale securities:

               

Net unrealized gain (loss)

    316       (54 )

Total comprehensive loss

  $ (2,962 )   $ (2,966 )

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

ASTROTECH CORPORATION

Condensed Consolidated Statement of Changes in Stockholders Equity

(In thousands)

(Unaudited)

 

   

优先股

                                                         
   

D轮

   

普通股

                                         
   

已发行股份数量

   

金额

   

已发行股份数量

   

金额

   

国债库存金额

   

额外实收资本

   

累计亏损

   

累计其他全面收益亏损

   

股东权益总额

 

截至2024年6月30日的余额

    281     $       1,702     $ 190,643     $ (119 )   $ 82,480     $ (237,020 )   $ (1,177 )   $ 34,807  

可供出售的市场证券的净变动

                                              316       316  

基于股票的补偿

                                  216                   216  

净损失

                                        (3,278 )           (3,278 )

截至2024年9月30日的余额

    281     $       1,702     $ 190,643     $ (119 )   $ 82,696     $ (240,298 )   $ (861 )   $ 32,061  

 

   

优先股

                                                         
   

D轮

   

普通股

                                         
   

已发行股份数量

   

金额

   

已发行股份数量

   

金额

   

国债库存金额

   

额外实收资本

   

累计亏损

   

累计其他全面收益亏损

   

股东权益总额

 

截至2023年6月30日的余额

    281     $       1,682     $ 190,643     $ (119 )   $ 81,002     $ (225,354 )   $ (1,453 )   $ 44,719  

可供出售的市场证券的净变化

                                              (54 )     (54 )

基于股票的补偿

                                  364                   364  

限制性股票的发行

                20                                      

净损失

                                        (2,912 )           (2,912 )

截至2023年9月30日的余额

    281     $       1,702     $ 190,643     $ (119 )   $ 81,366     $ (228,266 )   $ (1,507 )   $ 42,117  

 

请参阅审计未完的简明合并基本报表附注。

 

5

 

         ASTROTECH 公司及其子公司

简明合并现金流量表

(以千计)

(未经审计)

 

   

截至三个月

 
   

九月三十日

 
   

2024

   

2023

 

经营活动产生的现金流:

               

净损失

  $ (3,278 )   $ (2,912 )

调整净亏损与经营活动使用的现金的折算:

               

基于股票的补偿

    216       364  

折旧

    232       149  

营业租赁使用权资产的摊销

    36       36  

融资租赁的利息

    2       4  

资产和负债的变动:

               

应收账款

    (14 )     (166 )

存货净额

    (224 )     (195 )

应收所得税

          1  

应付账款

    276       100  

其他资产和负债

    (863 )     (394 )

与内部使用软件相关的融资负债的偿还

    (28 )      

经营租赁负债

    (41 )     (37 )

净现金流出活动

    (3,686 )     (3,050 )

投资活动的现金流:

               

购买房产和设备

    (193 )     (24 )

短期投资所得

          2,001  

投资活动产生的净现金(使用)提供

    (193 )     1,977  

融资活动产生的现金流:

               

融资租赁负债的还款

    (45 )     (45 )

融资活动所使用的净现金

    (45 )     (45 )

现金及现金等价物净变动额

  $ (3,924 )   $ (1,118 )

期初的现金及现金等价物

    10,442       14,208  

期末现金及现金等价物

  $ 6,518     $ 13,090  
                 
                 

现金流信息的补充披露:

               

支付的利息

  $ 4     $ 4  

已支付的所得税

  $ 1     $ 2  

 

请参阅审计未完的简明合并基本报表附注。

 

6

 

ASTROTECH公司及其子公司

 

未经审计的简明合并财务报表注释

 

(1) 一般信息

 

业务概况 

  

术语 “Astrotech”、“公司”、“我们”、“我们”、“我们的” 指的是 Astrotech Corporation(纳斯达克:ASTC),一家在特拉华州注册的公司。 1984. 

  

我们的使命是通过部署专门设计的设备,扩展对质谱("MS")及其使用的访问,以满足高成交量、实时测试环境中如机场、边境检查站、货物中心、基础设施安防、监狱、军工-半导体基地、执法中心和工业地点所需的适当精度水平。Astrotech质谱仪技术™(“AMS技术”)平台通过简化用户界面、自动化复杂的校准过程、加固关键元件以适应MS现场工作,并实现多种样本采集选项的配置来实现我们的使命。

  

我们正在通过以下描述的专门应用、全资子公司实现AMS科技的商业化。

 

Astrotech 科技公司(“ATI”)拥有和许可与AMS科技相关的知识产权。

  

第一检测 公司(“第一检测”)是一家制造爆炸物痕量探测器("ETDs")和毒品痕量探测器(“NTDs”)的公司,旨在用于安防-半导体和检测,在机场、边境检查站、货运中心、制造行业安全、监狱、军工-半导体基地和执法中心。 第一检测 拥有来自ATI的专有AMS科技许可,用于毒品、航空旅客和货物安防-半导体应用。

  

AgLAb, Inc.(“AgLAB”)正在开发一系列质谱仪,专注于大麻和大麻股市场,初步关注优化提炼过程中的产量。AgLAb从ATI获得了一项独家AMS科技许可,适用于农业行业中的应用,该应用需要分析存在于有机植物材料和提取物中的复杂化学化合物。

  

BreathTech公司(“BreathTech”)正在开发一种呼吸分析工具,用于筛查可能表明身体健康状况受损的挥发性有机化合物(“VOC”)代谢物,包括但不限于 细菌或病毒感染。BreathTech拥有来自ATI的呼吸分析应用独家AMS科技许可证。

  

Pro-Control, Inc.(“Pro-Control”)专注于将AMS科技应用于工业过程控制应用中。质谱仪和过程旨在测试、测量和提高工业过程中反应中间体的纯度和百分比产率。Pro-Control拥有ATI授予的AMS科技独家许可,用于农业行业以外的化学品蒸馏。

  

合并原则与呈现基础

 

根据美国通用会计准则(“GAAP”)编制Astrotech公司及其所有全资子公司的合并基本报表,需要管理层作出判断和估计并形成假设,这些假设会影响合并基本报表日期的资产和负债的报告金额以及报告期间的收入和费用的报告金额。估计和基本假设会持续进行审查。实际结果 可能 在不同的假设和条件下与这些估计不同。所有内部交易在合并中已被消除。操作结果为 截至月份 2024年9月30日 并不一定能反映出结果, 可能 可预期的结果是为年度结束于 2025年6月30日。 这些未经审计的压缩合并基本报表应与公司在 10-k截至 2024年6月30日的年度报告的合并基本报表及附注一起阅读。 某些前期金额已被重新分类,以符合当前年度的展示形式,或由于四舍五入进行了调整, 对净利润或股东权益的影响。  

  

7

 

段落信息

  

公司已经确定其符合会计标准编纂(“ASC”) “分部报告”的标准。管理层已得出结论,我们的首席运营决策者(“CODM”)是我们的首席执行官。 280 公司的CODM每月审查整个组织的合并结果,以评估绩效并做出资源分配决策。管理层将公司的运营视为一个业务,并管理其业务作为一个运营部门。

 

  

会计公告

  

2016年6月, 财务会计准则委员会发布了 ASU 2016-13,信用损失的计量 金融工具上的信用损失。ASU 2016-13要求 各实体采用基于当前预期信用损失(“CECL”)的前瞻性方法来估计某些类型金融工具的信用损失,包括交易应收款。该标准对公司自 2016年12月15日以后的基本报表期间生效。 2022.  ASU的采用 2016-13 2023年7月1日 对公司的基本报表产生了重大影响。

 

2023年7月 美国财务会计准则委员会(FASB) 发布了ASU第2023号-03,"财务报表的呈现主题205),收益表—综合收益的报告(主题 220), 区分负债与股权(主题 480), 股权(主题 505), 以及薪酬——股票薪酬(主题 718)根据SEC工作人员会计公报 没有。 120, 为公共公司在掌握重要的非公开信息时考虑参与基于股份的支付交易提供了解释性指导。此更新的生效日期为财政年度开始后的 包括该财政年度内的中期期间。对此进行采用 2024年7月1日 做到 对其基本报表产生了重大影响。

 

在2023年8月 2020年, FASB发布了 ASU第2020号-06,债务—可转换债务 及其他期权(小节470-20,以及衍生工具与对冲—实体自身股权中的合同(子主题 815-40): 对可转换金融工具和实体自有权益合同的会计处理。修订内容在 ASU 第2020号-第06号简化了 与适用GAAP相关的某些具有负债和权益特征的金融工具的复杂性。更具体来说,修订重点关注对可转换金融工具和实体自有权益合同的衍生范围例外的指导。对于较小的报告公司, ASU 第2020号-第06号自 2023年12月以后开始的财政年度生效 15, 2023,包括 这些财政年度内的中期。该标准的采用在 2024年7月1日 其基本报表产生了重大影响。

   

2023年11月, 财务会计准则委员会发布了会计准则更新 2023-07—分部 报告(主题 280):对可报告分部披露的改进。所有公共实体将被要求根据新指南在2023年12月15日以后年度期间开始报告分部信息。 2023年12月15日之后。对此的采用将于 2024年7月1日 对其基本报表产生了重大影响。

 

最近发布的会计标准 然而被采纳

  

2023年12月, FASB发布了ASU 2023-09, “所得税(主题 740):对所得税披露的改进”旨在提高所得税披露的透明度和决策有用性。该指导主要通过对税率调节和已缴所得税信息的更改,回应了投资者对增强所得税信息的请求。该指导适用于在 2024年12月15日之后。 我们正在评估该指导对我们披露的影响。

 

其他会计公告尚未生效, 管理层认为这些公告与公司目前或未来的合并基本报表相关或可能产生重大影响。

  

8

 

 

(2) 投资

 

下表总结了截至公司投资相关的收益和损失 2024年9月30日 2024年6月30日,分别是:

 

   

2024年9月30日

 

可供出售投资

 

调整后

   

未实现

   

未实现

   

公平

 

(以千计)

 

成本

   

增益

   

Loss

   

价值

 

共同基金 - 企业与政府债务

  $ 15,276     $     $ (643 )   $ 14,633  

ETF - 企业与政府债务

    7,375             (218 )     7,157  

总计

  $ 22,651     $     $ (861 )   $ 21,790  

 

   

2024年6月30日

 

可供出售投资

 

调整后

   

未实现

   

未实现

   

公平

 

(以千计)

 

成本

   

增益

   

Loss

   

价值

 

共同基金 - 公司的债务与政府的债务

  $ 15,276     $     $ (850 )   $ 14,426  

ETF - 公司的债务与政府的债务

    7,375             (327 )     7,048  

总计

  $ 22,651     $     $ (1,177 )   $ 21,474  

 

截至 2024年9月30日 以及 2024年6月30日,公司拥有 长期投资。有关公司金融工具公允价值的更多信息,请参见脚注 9.

 

下表列出了截至某个时间点某些金融工具的账面价值 2024年9月30日 2024年6月30日,分别是:

 

   

账面价值

   

账面价值

 
   

短期投资

   

Long-Term Investments

 

(以千计)

 

2024年9月30日

    2024年6月30日    

2024年9月30日

    2024年6月30日  

货币市场所有基金类型

                               

所有基金类型 - 企业与政府债务

  $ 14,633     $ 14,426     $     $  

ETF - 企业与政府债务

    7,157       7,048              

总计

  $ 21,790     $ 21,474     $     $  

 

 

(3) 租赁

 

2021年4月27日, Astrotech签署了一项新的租约,用于位于德克萨斯州奥斯汀的一个约 5,960 平方英尺的研发设施(“研发设施”),其中包括实验室、小型生产车间和员工办公室,尽管公司的许多员工仍然远程工作。租约于 2021年6月1日 开始,租期为 36 个月。于 2022年11月11日, 公司签署了研发设施的租赁延长协议,延长了租期至 2025年4月30日。 公司的总合同基础租金义务为 十一-月延长的金额约为$95千。

 

2022年11月22日, Astrotech签署了一项分租协议,以租用直接毗邻研发设施的额外设施(“分租设施”)。分租设施的面积约为 3,900 平方英尺,将为公司推出其AgLAb产品并继续在ATI和BreathTech进行研发工作提供所需空间。分租从 2022年12月1日开始, 并且租赁期限为 29 个月。公司对分租设施的总合同基本租赁义务约为$156 千。

 

9

 

经营租赁资产代表公司在租赁期限内使用基础资产的权利,租赁负债代表其因租赁产生的租赁付款义务。经营租赁资产和负债在开始日期时,根据租赁期限内租赁付款的现值确认。由于公司的租赁并未提供隐含利率,故公司在确定租赁付款的现值时使用其增量借款利率。在确定公司的增量借款利率时需要重大判断。租赁支付的租赁费用在租赁期限内以直线方式确认。融资租赁资产的摊销费用总计为 $ 千,适用于每个 31 截至月份 2024年9月30日 2023,分别。

 

公司的运营和融资租赁的资产负债表呈现如下:

 

(以千计)

 

在合并资产负债表上的分类

 

2024年9月30日

  

2024年6月30日

 

资产:

          

经营租赁资产

 

经营租赁,使用权资产,净值

 $83  $119 

融资租赁资产

 

物业及设备(净额)

 $335   366 

租赁资产总额

   $418  $485 
           

负债:

          

当前:

          

经营租赁义务

 

租赁负债,当前

 $97  $138 

融资租赁义务

 

租赁负债,当前

  52   89 

非流动负债:

          

经营租赁义务

 

租赁负债,非流动性

      

融资租赁义务

 

租赁负债,非流动性

  67   73 

租赁负债总额

   $216  $300 

 

截至未来最低租赁付款为 2024年9月30日 根据不可取消的租赁,具体如下(单位:千):

 

(以千计)

            

截至6月30日的年度

 

经营租赁

  

融资租赁

  

总计

 

2025

 $99  $49  $148 

2026

     27   27 

2027

     27   27 

2028

     25   25 

2029

         

之后

         

总租赁义务

  99   128   227 

减:隐含利息

  (2)  (9)  (11)

净最小租赁义务的现值

  97   119   216 

减:租赁负债 - 目前

  (97)  (52)  (149)

租赁负债 - 长期

 $  $67  $67 

 

其他信息截至 2024年9月30日,如下所示:

 

加权平均剩余租赁期限(年):

    

经营租赁

  0.6 

融资租赁

  1.0 

加权平均贴现率:

    

经营租赁

  6.1%

融资租赁

  5.4%

 

经营租赁的现金支付为 截至月份 2024年9月30日,以及 2023 总计为$43 千和$41 千,分别为。融资租赁的现金支付总计为$45每个一千 截至月份 2024年9月30日,以及 2023分别。

 

10

 
 

(4) 不动产和设备,净值

 

截至 2024年9月30日 以及 2024年6月30日, 所有者权益和设备,净值包括以下内容:

 

(以千计)

 

2024年9月30日

  

2024年6月30日

 

家具、固定装置、设备及租赁改善

 $3,807  $3,613 

软件

  881   881 

正在进行的资本改善

     1 

总财产和设备

  4,688   4,495 

累计折旧和摊销

  (1,964)  (1,732)

物业及设备(净额)

 $2,724  $2,763 

 

物业和设备的折旧和摊销费用为$232 千美元和$149 千美元为 截至月份 2024年9月30日2023,分别。总的折旧和摊销费用包括融资租赁使用权资产的摊销为$31 每个一千 截至月份 2024年9月30日 以及 2023,分别。

 

(5) 保修准备金

 

Astrotech为其客户提供所售产品的保修。这些保修通常在原始发货后的特定时间段内,如果出现问题,提供产品的维修和维护。与产品销售同时,公司记录预计保修费用的准备金,并相应增加营业成本。公司根据历史经验和预期费用定期调整该准备金。公司在发生时会将保修下实际的维修费用,包括零件和人工,计入该准备金。目前的保修准备金义务包含在合并资产负债表中的应计费用和其他负债中。保修准备金余额为$197 千和$184 2024年9月30日 以及 截至2024年6月30日。

 

(6) 股东 权益

 

优先股

 

公司已发行 280,898 系列D可转换优先股(“系列D优先股”)的股份,均已发行并在外流通。系列D优先股可以按 一个的比例转换为普通股。系列D优先股可以被公司召回。优先股的持有人有权获得,且我们应支付,与普通股支付的分红派息相等且形式相同的股份分红派息,当普通股支付分红派息时。一个 其他分红派息支付于优先股。优先股具有 投票权。在公司清算、解散或结束时,无论是自愿还是非自愿,优先股优先于普通股。D系列优先股的持有人有权选择将该等股份转换为普通股。

 

优先股的持有人之前与公司达成协议,他们将 在公司章程修正案(即“章程修正案”)被接受提交至特拉华州之前, “2020 这一过程发生在 2021年10月。

 

普通股

 

公司已发行了 1,712,045 的普通股,并且有 1,701,729 截至 2024年9月30日开始。 库藏股为 10,316 是发行股与流通股之间的差额。

 

我们进行了 在期间发行普通股 截至月份 2024年9月30日。

 

11

 

权利计划

 

2022年12月21日, 公司董事会采用了一项有限期限的股东权利计划(“权利计划”),初步于 2023年12月20日 并宣布每一股普通股将派发 一个 优先认购权给截至 2023年1月5日的股东。 从公司购买 一一-千分之一的公司系列A特别优先股,面值$0.001 每股的行使价格为$58.00 一旦权利可行使,需遵守相关权利协议中的条款及调整。

 

2023年12月18日, 公司与Equiniti信托公司作为权利代理人签署了协议修正案, 没有。 1 将最终到期日(在权利计划中定义)延长至 2024年12月20日, 除非公司进一步延长最终到期日,或根据权利计划的条款,公司提前赎回或交换与权利计划相关的权利。所有其他权利计划的条款和条件保持不变。

 

认购权证

 

以下是关于普通股认股权证活动的总结, 截至月份 2024年9月30日如下所示:

 

   

认股权证所对应的股份数量(以千为单位)

   

加权平均行使价格

   

发行时的总公平市场价值(以千为单位)

   

加权平均剩余合同期限(年)

 

截至2024年6月30日的业绩

    80     $ 72.10     $ 3,747       1.60  

发行的warrants

                       

warrants已行使

                       

认股权证到期

                       

截至2024年9月30日的未偿还期权

    80     $ 72.10     $ 3,747       1.35  

 

 

(7) 每股净亏损

 

基本每股净亏损是根据报告期间已流通普通股的加权平均股数计算的。稀释每股净亏损是根据报告期间已流通普通股的加权平均股数加上潜在稀释普通股的影响计算的,使用的是库藏股票法和转股法。潜在稀释普通股包括已发行的期权和基于股份的奖励。

 

下表列出了用于计算基本和摊薄每股净亏损的分子和分母:

 

   

截至三个月

 
   

九月三十日

 

(以千为单位,除每股数据外)

 

2024

   

2023

 

分子:

               

净损失

  $ (3,278 )   $ (2,912 )

分母:

               

每股基本和摊薄净亏损的分母 — 加权平均流通普通股数量

    1,631       1,631  

每股普通股的基本和摊薄净亏损:

               

每股普通股净亏损。

  $ (2.01 )   $ (1.79 )

 

12

 

所有未归属的限制性股票奖励和可转换D系列优先股的 截至月份 2024年9月30日 计入每股摊薄净损失,因为对每股净损失的影响将是反摊薄的。期权购买 216,911 以$的行使价格购买普通股7.47 到$175.50 截至每股 2024年9月30日 包含在摊薄每股净亏损中,因为对每股净亏损的影响将是反摊薄的。

 

(8) 营业收入确认

 

Astrotech 根据会计标准分类法(“ASC”)主题下描述的公认营业收入确认方法确认营业收入 606 “来自客户合同的收入” ( “主题 606”),该主题在公司的财年中被采用 2019. 使用的方法基于合同类型以及产品和服务的提供方式。主题的指南 606 建立了一种 -步流程来管理来自客户合同的营业收入的确认和报告。该 步骤包括:(i) 确定与客户的合同,(ii) 确定合同中的履约义务,(iii) 判断交易价格,(iv) 将交易价格分配给合同中的履约义务,以及 (v) 在履约义务满足时确认营业收入。营业收入在与主题中的指引一致的时间点被确认。 606. 

 

合同资产和负债。公司签订合同以销售产品和提供服务,并确认由这些交易产生的合同资产和负债。公司根据主题确认营业收入及相关的应收账款。 606有时,公司会在合同赋予我们开具客户发票的权利之前提前确认营业收入。公司 可能 根据合同条款,在转移货物给客户之前,也会收到客户的对价。公司将客户的存款记录为递延营业收入。此外,公司 可能 在合同开始时以及提供服务之前,通常会收到服务和保修合同的付款。在这种情况下,公司记录递延营业收入负债。当满足所有营业收入确认标准后,公司将这些合同负债确认销售。

 

实用的权宜之计。在公司在客户获得货物控制权后负责运输的情况下,公司选择将运输活动视为履行活动,而不是单独的履行义务。此外,公司选择仅在摊销期超过  一个 年时,才考虑客户协议是否存在融资成分。只有当货物和服务转移与客户付款之间的时间间隔大于  一个 年。

 

产品销售。公司在发货或交付时根据每笔销售的条款及收款的可能性确认产品销售的营业收入,当产品控制权转移给客户时。如果产品销售的条款包含主观的客户接受标准,营业收入会被递延,直到公司达成接受标准,除非客户接受标准是表面或无关紧要的。公司通常为客户提供的付款条款为 60 天或更少。

 

货物运输。 公司将向客户收取的运输和处理费用记录为营业收入,并将相关成本记录为营业收入成本。

 

多个履约义务。某些与客户的协议涉及销售设备,包含多个要素,在合同中的义务是独立的,因此需要分离为多个履约义务,营业收入确认指引要求根据其相对单独销售价格将合同对价分配给每个独立的履约义务。分配给每个履约义务的价值会在每个独立承诺或承诺组合所满足的营业收入确认标准被满足时确认收入。

 

每项履约义务的独立销售价格是指实体在交易所转让商品或服务时预期有权获得的对价金额。 一个 当合同仅与一项履约义务相关时,全部对价金额归属该义务。 首先 当合同包含多项履约义务时,独立销售价格是使用可观察价格估算的,通常是适用折扣后的清单价格或在类似情况下出售商品或服务时的价格。 在销售价格可以直接观察的情况下,公司将使用可用信息估算独立销售价格,包括市场评估和预期成本,加上利润。

 

每项特定履行义务的完成时间表可以在短时间内完成,并且完全在一个报告期内,也可以在多个报告期内完成。每项履行义务的营业收入确认时间 可能 将取决于几个里程碑,包括设备的实际交付、现场验收测试的完成,以及在售后消耗品和服务交付的情况下,时间的推移。

 

13

 
 

(9公允价值计量

 

ASC主题 820 “公允价值计量”(“主题 820”)定义公允价值,建立了一个基于市场的公允价值计量框架或等级,并扩展了关于公允价值计量的披露。主题 820 在资产和负债按照公允价值计量并包含在基本报表中时适用。主题 820 中建立的公允价值等级优先考虑用于估值技术的输入,分为 级别,如下所示:

 

级别 1 - 在活跃市场上对相同资产或负债的报价。

 

级别 2 - 除级别以外的其他输入 1 可以直接或间接观察到的,例如类似资产或负债的报价价格,活跃市场中的报价, 或者其他可观察的输入,或可通过可观察市场数据对资产或负债的整个期限进行证实的输入。

 

级别 3 - 不可观察的输入,支撑的市场活动很少, 对于资产或负债的公允价值具有重要意义。

 

下表列出了截至某个时间点的某些金融工具的账面价值、估计公允价值和估值输入层级。 2024年9月30日 2024年6月30日:

 

   

2024年9月30日

 
   

账面

   

公允价值测量使用

   

公平

 

(以千计)

 

金额

   

一级

   

二级

   

第三级

   

价值

 

可供出售投资

                                       

短期投资

                                       

共同基金 - 公司的债务与政府的债务

    14,633       14,633                   14,633  

ETF - 公司的债务与政府的债务

    7,157       7,157                   7,157  

可供出售的总投资

  $ 21,790     $ 21,790     $     $     $ 21,790  

 

   

2024年6月30日

 
   

账面

   

公允价值测量使用

   

公平

 

(以千计)

 

金额

   

一级

   

二级

   

第三级

   

价值

 

可供出售投资

                                       

短期投资

                                       

共同基金 - 公司的债务与政府的债务

    14,426       14,426                   14,426  

ETF - 公司的债务与政府的债务

    7,048       7,048                   7,048  

可供出售投资总额

  $ 21,474     $ 21,474     $     $     $ 21,474  

 

可供出售证券的价值基于第一级 1 输入的定价来源于 , 在满足1月 Tranche b 支付之后,向持有者支付,直到根据票据第2(e)条款支付的剩余 未偿本金和应计未支付的利息全额支付(“第三方定价供应商,他们使用活跃市场中相同资产的报价价格。 2 公允价值测量对于定期存款被视为第 , 在满足1月 Tranche b 支付之后,向持有者支付,直到根据票据第2(e)条款支付的剩余 未偿本金和应计未支付的利息全额支付(“并使用来自第三方定价供应商的定价,这些供应商使用活跃和非活跃市场中相同或类似证券的报价价格。

 

在简明合并资产负债表中,报告的现金及现金等价物、短期投资、应收账款、应付账款、应计费用及其他负债的账面价值以公允价值或成本计量,因这些工具的产生与预期实现之间时间较短,且其当前市场利率与公允价值相近。

 

截至未经审计的简明合并资产负债表日期,某些投资证券需要按公允价值记录,并且期间公允价值的变化将作为未实现的收益或损失记录。

 

(10) 业务风险和信用风险集中涉及现金

 

公司截至2024年11月4日有 一个客户在实质上构成了公司所有的营业收入, 截至月份的营业结果 2024年9月30日。为了 截至月份 2023年9月30日, 公司拥有 两个 客户在很大程度上构成了公司所有板块的营业收入。

 

公司在银行账户中维持的所有基金类型 可能 超过联邦存款保险公司("FDIC")保险限额。这些未投保余额的损失风险通过存入公司认为信用质量高的金融机构的资金来减轻。公司有 在这些账户中经历过损失。

 

14

 
 

(11)基于股票的薪酬

 

股票期权活动总结

 

公司的股票期权活动为 截至月份 2024年9月30日 如下:

 

    股份    

加权平均行使价格

 

截至2024年6月30日的未偿余额

    156,628     $ 14.18  

授予

    66,210       11.10  

已行使

           

已取消或过期

    (5,927 )     9.39  

截至2024年9月30日的未偿还金额

    216,911     $ 13.37  

 

The aggregate intrinsic value of options exercisable at September 30, 2024 was $0, as the fair value of the Company’s common stock is less than the exercise prices of these options. The aggregate intrinsic value of all options outstanding at  September 30, 2024 was $1 thousand.

 

The table below details the Company’s stock options outstanding as of September 30, 2024:

 

Range of exercise prices

    Number Outstanding     Options Outstanding Weighted-Average Remaining Contractual Life (Years)     Weighted-Average Exercise Price     Number Exercisable     Options Exercisable Weighted-Average Exercise Price  
$ 7.47 - 19.20       214,286       9.08     $ 11.67       54,626     $ 13.45  
$ 55.50 - 84.90       418       4.11       61.52       418       61.52  
$ 159.00 - 175.50       2,207       2.61       168.97       2,207       168.97  
$ 7.47 - 175.50       216,911       9.00     $ 13.37       57,251     $ 19.79  

 

Compensation costs recognized related to stock option awards were $155 thousand and $56 thousand for each of the three months ended September 30, 2024 and 2023, respectively. The remaining stock-based compensation expense of  $1.5 million related to stock options will be recognized over a weighted-average period of 2.32 years.

 

Restricted Stock

 

The Company’s restricted stock activity for the three months ended September 30, 2024, is as follows:

 

      Shares     Weighted Average Grant Date Fair Value  

Outstanding at June 30, 2024

    43,773     $ 15.36  

Granted

           

Vested

    (6,668 )     10.10  

Canceled or expired

           

Outstanding at September 30, 2024

    37,105     $ 16.30  

 

Stock compensation expenses related to restricted stock were $61 thousand and $308 thousand for the three months ended September 30, 2024 and 2023, respectively.  The remaining stock-based compensation expense of $489 thousand related to restricted stock awards granted will be recognized over a weighted-average period of 2.27 years.

 

15

 
 

(12) Income Taxes

 

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of September 30, 2024 the Company has a valuation allowance against all of its net deferred tax assets.

 

For the three months ended September 30, 2024 and 2023, the Company incurred pre-tax losses in the amount of $3.3 million and $2.9 million, respectively. The total effective tax rate was approximately 0% for the three months ended September 30, 2024 and 2023.

 

For each of the three months ended September 30, 2024 and 2024, the Company’s effective tax rate differed from the federal statutory rate of 21%, primarily due to the valuation allowance placed against its net deferred tax assets. 

 

The Inflation Reduction Act and the Chips and Science Act were enacted in August 2022.  There is no material impact to the Company from these new tax laws.

 

FASB ASC 740, “Income Taxes” addresses the accounting for uncertainty in income tax recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. The Company currently has approximately $593 thousand of uncertain tax positions as of September 30, 2024, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.

 

Loss carryovers are generally subject to modification by tax authorities until three years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended 2001 through present for federal purposes and fiscal years ended 2006 through present for state purposes.

 

 

(13) Commitments and Contingencies

 

The Company is not subject to any litigation at the present time.

 

From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of a number of factors including experience with similar matters, past history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the final outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.

 

The Company establishes reserves for the estimated losses on specific contingent liabilities, for regulatory and legal actions where the Company deems a loss to be probable and the amount of the loss can be reasonably estimated. In other instances, the Company is not able to make a reasonable estimate of liability because of the uncertainties related to the outcome or the amount or range of potential loss.

 

However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. 

 

 

(14) Subsequent Events

 

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements.

 

16

 
 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words “may,” “will,” “plans,” “believes,” “estimates,” “expects,” “intends,” and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:

 

 

The adverse impact of recent inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east region, and the COVID-19 pandemic;

 

 

Our ability to successfully pursue our business plan and execute our strategy, including our collaboration with Cleveland Clinic;

 

 

The effect of economic and political conditions in the United States or other nations that could impact our ability to sell our products and services or gain customers;

 

 

Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers;

 

 

The impact of trade barriers imposed by the U.S. government, such as import/export duties and restrictions, tariffs and quotas, and potential corresponding actions by other countries in which we conduct our business;

 

 

Technological difficulties and potential legal claims arising from any technological difficulties;

 

 

The risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation;

 

 

Uncertainty in government funding and support for key programs, grant opportunities, or procurements;

 

 

The impact of competition on our ability to win new contracts;

 

 

Our ability to meet technological development milestones and overcome development challenges; and

 

 

Our ability to successfully identify, complete and integrate acquisitions.

 

While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others identified herein.

 

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. 

  

17

 

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our 2024 Annual Report on Form 10-K (“Form 10-K”), elsewhere in this Quarterly Report on Form 10-Q , or those discussed in other documents we filed with the SEC. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the Securities and Exchange Commission (“SEC”) or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications. 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report.

 

Business Overview

 

The terms “Astrotech”, “the Company”, “we”, “us”, or “our” refer to Astrotech Corporation (Nasdaq: ASTC), a Delaware corporation organized in 1984. Our use of “products” and “devices” refer to the TRACER 1000™, BreathTest-1000™, AGLAB 1000™, and Pro-Control 1000™ along with related accessories and consumables. 

  

Our mission is to expand access to mass spectrometry (“MS”) and its use through the deployment of devices designed specifically for the appropriate levels of precision required in high-volume, real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. We achieve our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS field work, and enabling multiple configurations for sample intake options. 

  

Since the Tracer 1000 was certified by the European Civil Aviation Conference (“ECAC”) in 2019, our customers have deployed our devices in approximately 30 locations across 14 countries throughout Europe and Asia. We are commercializing the Astrotech Mass Spectrometer Technology™ platform (“AMS Technology”) through application specific, wholly-owned subsidiaries. 

 

Astrotech Technologies, Inc. 

  

ATI owns and licenses the AMS Technology, the platform MS technology originally developed by 1st Detect. The AMS Technology has been designed to be inexpensive, smaller, and easier to use when compared to traditional mass spectrometers. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 17 patents granted along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to four wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1st Detect for use in security and detection applications, to AgLAB for use in the agriculture application, to BreathTech for use in breath analysis applications, and to Pro-Control for use in production applications. 

  

18

 

1st Detect Corporation 

  

1st Detect, a licensee of ATI for security and detection applications, has developed the TRACER 1000™, the world’s first MS based ETD certified by the ECAC and approved by TSA for air cargo. The TRACER 1000 was designed to outperform the ETDs currently used at airports, cargo and other secured facilities, and borders worldwide. The Company believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). The Company further believes that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument’s performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000’s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library. 

  

In order to sell the TRACER 1000 to airport and cargo security customers in the European Union and certain other countries, we obtained ECAC certification. The Company is currently selling the TRACER 1000 to customers who accept ECAC certification.  As of September 30, 2024, the Company has deployed the TRACER 1000 in approximately 30 locations in 14 countries throughout Europe and Asia. 

 

In June of 2024, the TSA approved 1st Detect’s TRACER 1000 for the Air Cargo Security Technology List, which advanced the TRACER 1000 to Stage II testing and permits air cargo companies in the United States to use our equipment in their operations. During Stage II testing, the Company is conducting field trials with the TSA. If field trials are successful, the TRACER 1000 will be added to the "qualified" list.

 

The Company has also started the process to pass TSA checkpoint testing. This process involves Developmental Test and Evaluation in which the Transportation Security Laboratory ("TSL") will test the TRACER 1000 and work with 1st Detect to ensure its readiness to enter certification testing. The certification test is then completed by the Independent Test & Evaluation department of TSL. As of the fiscal year 2023 budget the government had over 6,000 ETD units at checkpoint and baggage screening points for which we believe that the TSA would benefit from utilizing our AMS Technology. 

  

In May 2023, we successfully delivered a purchase order for 14 ETDs from a Romania-based company focused on research and innovation in the security and telecommunications space.   During the second fiscal quarter of 2024, we delivered a purchase order for seven of our TRACER 1000 explosives trace detectors for an airport security checkpoint, which were deployed in an airport in Romania.  

  

We are currently accepting orders for the TRACER 1000 ETD and NTD which are listed in the U.S. General Services Administration ("GSA") IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290 in April 2024. The TRACER 1000 ETD and NTD are high-performance laboratory instruments capable of rapid detection of trace levels of explosive and narcotic compounds in seconds. The TRACER 1000 ETD and NTD both provide a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement.  

  

IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U.S. federal government, one of the largest buyers of goods and services in the world.  

  

We continue to showcase the TRACER 1000 NTD and ETD at the trade events in the U.S. 

 

AgLAB Inc. 

  

AgLAB, an exclusive licensee of ATI for the use in the agriculture industry to analyze complex chemical compounds found in organic plant material and extracts, has developed the AgLAB 1000™ series of mass spectrometers for use in the hemp and cannabis markets with the initial focus on optimizing yields in the distillation process. The AgLAB product line is a derivative of the Company’s core AMS Technology. AgLAB continues to conduct field trials demonstrating that the AgLAB 1000-D2™ can be used in the distillation process to significantly improve the yields of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) oil during distillation. The AgLAB 1000-D2™ uses the Maximum Value Process solution (“MVP”) to analyze samples in real-time and assist the equipment operator determining the ideal settings required to maximize yields.  

  

19

 

Production and processing of hemp and cannabis is a huge, worldwide industry. In the U.S., for example, the wholesale value of the cannabis crop from just the U.S. states permitting adult-use and medical cannabis exceeds $6 billion annually. We believe growth in the U.S. and in the worldwide market is likely fed in part by the growing acceptance of medicinal cannabis products and anticipated legislative changes in various jurisdictions worldwide. We also believe this growth is due in part to the passage of the 2018 Farm Bill, which legalized hemp production in the U.S. 

  

As the CBD and hemp market continues to grow, there has been an influx of new companies entering the CBD and THC supply chains, ranging from large corporations to small startups. These companies comprise AgLAB’s target market. The competition within the supply chain is fierce, with companies investing heavily in research and development to create innovative products and differentiate themselves from their competitors. However, the market remains highly fragmented, with many products of varying quality and efficacy, making it challenging for consumers to navigate. Overall, the CBD and hemp market in the U.S. is a rapidly growing industry with significant potential for continued expansion. As more research is conducted and regulations are established, we believe it is likely that the market will become more standardized and regulated, leading to increased consumer confidence and demand. Stakeholders in the industry are likely to face challenges as it matures, including increased competition and potential regulatory hurdles. 

 

Management believes the AgLAB 1000-D2™ will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for distillation processors of hemp and cannabis. The use of the AgLAB 1000-D2™ should reduce waste from current distillation practices and result in a significantly improved product. Due in large part to the Company’s proprietary technology, the Company believes it is the only provider of a mass spectrometry system that gives it a distinct advantage in the industry. Sales efforts for the AgLAB 1000-D2 are currently underway.  

  

AgLAB announced the presentation of the AgLAB Maximum Value Processing at MJBizCon.  The AgLAB MVP is an innovative process control system proven to increase the potency of ending-weight yields and increase revenue.  The AgLAB MVP process provides real-time data, allowing distillers to adjust parameters to optimize the quality and quantity of each batch of oil.  During our field trials of the AgLAB MVP, we were able to improve ending-weights yields by 20% or more. We believe these ongoing field trials demonstrate the solution can be a valuable tool for cannabis and hemp oil processors worldwide. 

  

On June 13, 2024, AgLAB and SC Laboratories (“SC Labs”) entered into a master lease agreement providing for the joint marketing of the AgLAB 1000-D2™ mass spectrometer and the AgLAB Maximum Value Process™ testing method to SC Labs’ clients. 

   

BreathTech Corporation 

  

BreathTech, an exclusive licensee of ATI for use in breath analysis applications, is developing the BreathTest-1000™, a breath analysis tool to screen for VOC metabolites found in a person’s breath that could indicate they may have compromised condition including but not limited to a bacterial or viral infection. The Company believes that new tools to quickly identify the presence of a VOC metabolite could play an important role in detecting and containing airborne diseases. 

  

In June 2022, the Company expanded its existing study that initially focused on COVID-19 with Cleveland Clinic to use the BreathTest-1000 to screen for a variety of diseases spanning the entire body. The project focused on detecting bloodstream infections and respiratory infections. While the Joint Development Agreement with Cleveland Clinic remains active, we believe the work to commercialize this application of the AMS Technology will require many years and significant investment due to regulatory requirements and have determined to deploy capital instead to our other business units. We are also exploring how the advancements and knowledge derived from our research on the BreathTech use case can be applied in our other existing and potential new business units. 

 

Pro-Control, Inc. 

  

On December 12, 2023, we announced the formation of our new wholly-owned subsidiary, Pro-Control, and ATI’s entry into an exclusive license with Pro-Control to utilize our AMS Technology for industrial process control applications involving chemical distillation outside of the agriculture industry. Pro-Control uses advanced mass spectrometer instrumentation to monitor and control the production and operations of manufacturing processes using real-time, in-process samples. Pro-Control provides the vital spectral qualitative and quantitative data needed to control the production parameters (temperatures, flow, speed, and pressure) while significantly improving efficiency. 

  

Pro-Control has introduced its proprietary Pro-Control Maximum Value Processing and the Pro-Control 1000-D2™ mass spectrometer, which in combination are designed to test, measure and increase reaction intermediates, purity and percent yields in industrial processes.  

 

20

 

Critical Accounting Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). The preparation of these financial statements requires us to make estimates and judgments that directly affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. A critical accounting estimate is one that involves a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management continuously evaluates its critical accounting policies and estimates, including those used in evaluating the recoverability of long-lived assets, recognition of revenue, valuation of inventory, and the recognition and measurement of loss contingencies, if any. Actual results may differ from these estimates under different assumptions or conditions.  We believe that the following accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements.

 

Results of Operations

 

Three months ended September 30, 2024, compared to three months ended September 30, 2023:

 

Selected consolidated financial data for the quarters ended September 30, 2024, and 2023 is as follows:

 

   

Three Months Ended September 30,

 

(In thousands)

 

2024

   

2023

 

Revenue

  $ 34     $ 425  

Cost of revenue

    25       242  

Gross profit

    9       183  

Gross margin

    26 %     43 %

Operating expenses:

               

Selling, general and administrative

    1,688       1,646  

Research and development

    1,949       1,872  

Total operating expenses

    3,637       3,518  

Loss from operations

    (3,628 )     (3,335 )

Other income and expense, net

    350       423  

Income tax expense

           

Net loss

  $ (3,278 )   $ (2,912 )

 

Revenue – Total revenue decreased by $391 thousand during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024. In the first quarter of fiscal year 2025 revenue was related to ongoing consumable and recurring maintenance services of the TRACER 1000. In the first quarter of fiscal year 2024, revenue was related to the sales of our TRACER 1000 along with ongoing consumable and recurring maintenance services of the TRACER 1000. The decrease in revenue is the result of not selling devices during the first quarter of fiscal year 2025.

 

Cost of Revenue – Gross profit is comprised of revenue less cost of revenue. Our costs of revenue include labor, materials, overhead, shipping, and warranty expenses. Cost of revenue decreased by $217 thousand during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024, because of the decrease in device sales. Gross margin decreased by 17% in the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024. The decrease in device sales resulted in a decrease in gross margin.

 

 

21

 

Operating Expenses – Operating expenses increased $119 thousand, or 3.4%, during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024. Significant changes to operating expenses include the following:

 

 

Selling, general and administrative expenses increased $42 thousand, or 2.6%, during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024 due to increases in marketing and selling activities which were partially offset by a decrease in legal fees and personnel costs.

 

 

Research and development expenses increased $77 thousand, or 4.1%, during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024, largely driven by increases in personnel count to support the development of our mass spectrometry offering and expenses related to cross-platform improvements to our technology.

 

Other Income and Expense, net – Other income and expense, net decreased $73 thousand during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024, due to less investments earning interest income.

 

Income Taxes Income tax expense had minimal change during the first quarter of fiscal year 2025, compared to the first quarter of fiscal year 2024.

 

Liquidity and Capital Resources

 

Cash Flows

 

The following is a summary of the change in our cash and cash equivalents:

 

   

Three Months Ended September 30,

 

(In thousands)

 

2024

   

2023

   

Change

 

Change in cash and cash equivalents:

                       

Net cash used in operating activities

  $ (3,686 )   $ (3,050 )   $ (636 )

Net cash used in investing activities

    (193 )     1,977       (2,170 )

Net cash used in financing activities

    (45 )     (45 )      

Net change in cash and cash equivalents

  $ (3,924 )   $ (1,118 )   $ (2,806 )

 

Cash and Cash Equivalents

 

As of September 30, 2024, we held cash and cash equivalents of $6.5 million, and our working capital was approximately $29.5 million. As of June 30, 2024, we had cash and cash equivalents of $10.4 million, and our working capital was approximately $32.2 million. Cash and cash equivalents decreased $3.9 million as of September 30, 2024, compared to June 30, 2024, due to funding our continuing operating expenses.

 

Operating Activities

 

Cash used in operating activities increased $636 thousand for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, due to operating expenses, and increases in executive officers bonuses and other liabilities.

 

Investing Activities

 

Cash used in investing activities decreased $2.2 million for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, due primarily to not purchasing short-term time deposit investments. The Company also acquired equipment in the three months ended September 30, 2024 of $0.2 million.

 

Financing Activities

 

Cash used in financing activities remained the same for the three months ended September 30, 2024, compared to the three months ended September 30, 2023. 

 

We did not have any material off-balance sheet arrangements as of September 30, 2024.

 

22

 

Liquidity

 

There have been no material updates to our expectations for our short- and long-term liquidity and operating capital requirements since our Annual Report on Form 10-K for the year ended June 30, 2024.  

 

Income Taxes

 

Provision for Income Tax

 

The Company’s effective tax rate is 0% for income tax for the three months ended September 30, 2024 and the Company expects that its effective tax rate for the full fiscal year 2025 will be 0%.  Based on the weight of available evidence, including net cumulative losses and expected future losses, the Company has determined that it is more likely than not that its U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets.

 

In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change net operating loss (NOL) carryforwards is subject to an annual limitation under Section 382 of the Internal Revenue Code. Generally, U.S. state laws have laws similar to Internal Revenue Code Section 382. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforward before utilization.

 

The Company files U.S. federal and state income tax returns.  The Company is not currently subject to any income tax examinations. The Company has net operating loss carryovers dating back to the June 2002 year, which generally allows all tax years to remain open to income tax examinations for all years for which there are loss carryforwards.

 

Uncertain Tax Positions

 

The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. The Company currently has approximately $593 thousand of uncertain tax positions as of September 30, 2024, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.
  

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

ITEM 4.  CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. Management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2024 at the reasonable assurance level.

 

Changes in Internal Controls over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

23

 

PART II: OTHER INFORMATION

 

ITEM 1.  LEGAL PROCEEDINGS

 

From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of a number of factors including experience with similar matters, past history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the final outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.

 

ITEM 1A. RISK FACTORS

 

Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our Form 10-K and our Form 10-Qs, the occurrence of any one of which could have a material adverse effect on our actual results.

 

There have been no material changes to the risk factors and other cautionary statements described under the heading “Item 1A Risk Factors” included in our Form 10-K for the fiscal year ended June 30, 2024.

 

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4.  MINE SAFETY DISCLOSURE

 

Not applicable.

 

ITEM 5.  OTHER INFORMATION

 

None.

 

24

 
 

ITEM 6.  EXHIBITS

 

Exhibit

No.

 

Description

 

Incorporation by

Reference

         

3.1

 

Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware.

 

Exhibit 3.1 to Form 8-K filed on December 28, 2017.

         

3.2

 

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed with the Securities and Exchange Commission on August 1, 2023).

 

Exhibit 3.1 to Form 8-K filed on August 1, 2023.

         

3.3

 

Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware.

 

Exhibit 3.3 to Form 8-K filed on December 28, 2017.

         

3.4

 

Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019.

 

Exhibit 3.2 to Form 8-K filed on April 23, 2019.

         

3.5

 

Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.

 

Exhibit 3.1 to Form 8-K filed on July 1, 2020.

         

3.6

 

Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.

 

Exhibit 3.1 to Form 8-K filed on October 12, 2021.

         
3.7   Third Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.   Exhibit 3.1 to Form 8-K filed on November 23, 2022.
         
4.1   Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, dated as of December 21, 2022.   Exhibit 4.1 to Form 8-K filed on December 21, 2022.
         
4.2   Amendment No. 1 to Rights Agreement dated as of December 18, 2023 to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21, 2022.   Exhibit 4.2 to Form 8-K filed on December 18, 2023.
         

31.1

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

 

Filed herewith.

         

31.2

 

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

 

Filed herewith.

         

32.1

 

Certification pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934.

 

Furnished herewith.

         

101.INS

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

Filed herewith.

         

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

Filed herewith.

         

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

Filed herewith.

         

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

Filed herewith.

         

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

Filed herewith.

         

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

Filed herewith.

         

104

 

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, has been formatted in Inline XBRL.

   

 

25

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

Astrotech Corporation

     

Date: November 13, 2024

 

/s/ Jaime Hinojosa

   

Jaime Hinojosa

   

Chief Financial Officer, Treasurer and Secretary

(Principal Financial and Accounting Officer)

 

26